Common Stock, Shares Authorized of CITIUS ONCOLOGY, INC. from 31 Dec 2021 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: shares
- Description
- The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
- Summary
-
CITIUS ONCOLOGY, INC. quarterly Common Stock, Shares Authorized in shares history and change rate from 31 Dec 2021 to 31 Dec 2025.
- CITIUS ONCOLOGY, INC. Common Stock, Shares Authorized for the quarter ending 31 Dec 2025 was 400,000,000, a 300% increase year-over-year.
- Source SEC data
- View on sec.gov
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Change (%)
CITIUS ONCOLOGY, INC. Quarterly Common Stock, Shares Authorized (shares)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 400,000,000 | +300,000,000 | +300% | 31 Dec 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q3 2025 | 400,000,000 | +300,000,000 | +300% | 30 Sep 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q2 2025 | 400,000,000 | +250,000,000 | +167% | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q3 |
| Q1 2025 | 100,000,000 | -50,000,000 | -33% | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q2 |
| Q4 2024 | 100,000,000 | -50,000,000 | -33% | 31 Dec 2024 | 10-Q | 14 Feb 2025 | 2025 | Q1 |
| Q3 2024 | 100,000,000 | 0 | 0% | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY |
| Q2 2024 | 150,000,000 | 0 | 0% | 30 Jun 2024 | 10-Q | 09 Aug 2024 | 2024 | Q2 |
| Q1 2024 | 150,000,000 | 0 | 0% | 31 Mar 2024 | 10-Q | 20 May 2024 | 2024 | Q1 |
| Q4 2023 | 150,000,000 | 0 | 0% | 31 Dec 2023 | 10-Q | 09 Aug 2024 | 2024 | Q2 |
| Q3 2023 | 100,000,000 | -50,000,000 | -33% | 30 Sep 2023 | 10-K | 27 Dec 2024 | 2024 | FY |
| Q2 2023 | 150,000,000 | 30 Jun 2023 | 10-Q | 16 Aug 2023 | 2023 | Q2 | ||
| Q1 2023 | 150,000,000 | 31 Mar 2023 | 10-Q | 15 May 2023 | 2023 | Q1 | ||
| Q4 2022 | 150,000,000 | 0 | 0% | 31 Dec 2022 | 10-K | 16 Apr 2024 | 2023 | FY |
| Q3 2022 | 150,000,000 | 30 Sep 2022 | 10-Q | 28 Nov 2022 | 2022 | Q3 | ||
| Q4 2021 | 150,000,000 | 31 Dec 2021 | 10-K | 17 Apr 2023 | 2022 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.